2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
May 16th 2022
Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.
May 16th 2022
Patients with low-grade non-muscle invasive bladder cancer who received the chemoablative reverse thermal gel UGN-102 were found to have maintained health-related quality-of-life outcomes.
April 25th 2022
Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.
April 13th 2022
The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.
February 19th 2022
Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.
February 18th 2022
Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.
January 22nd 2022
Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.
December 15th 2021
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.
December 12th 2021
The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.
December 9th 2021
Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer
December 8th 2021
Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.
September 10th 2021
CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.
September 9th 2021
Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.
September 8th 2021
The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.
June 11th 2021
Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.
June 6th 2021
Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.
June 4th 2021
The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.
March 20th 2021
Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
February 13th 2021
February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.